Archimedes Pharma announces UK launch of Zibor

Archimedes Pharma has announced the expansion of its critical care portfolio in the UK with the launch of Zibor (bemiparin sodium).

The compound is a second-generation low molecular weight heparin (LMWH) and the first drug of this kind to be licensed in the UK as a treatment for post-operative initiation of thromboprophylaxis in patients undergoing general and orthopaedic surgery.

Archimedes said Zibor will enter the UK market as the lowest-priced LMWH, while it is already used in over five million patients across the world.

It added the compound has shown its efficacy and safety in clinical trials, showing the highest anti-factor Xa:IIa ratio of all licensed LMWHs.

Richard de Souza, chief executive officer of the company, said: “Zibor fits well into our existing portfolio in critical care and we believe our commercial team will successfully unlock its considerable potential, contributing further to the strong ongoing growth of our UK operations.”

He added that the compound can be clearly differentiated from its competitors and addresses a large market that is also growing.

Earlier this month, Archimedes Development, a subsidiary of Archimedes Pharma, announced the purchase of an intellectual property portfolio relating to chitosan derivatives from Fennopharma.